aTyr Pharma (ATYR) AI Stock Analysis

• Market Cap: $95.07M
• Dividend Yield: N/A
• Average Volume (3M): 1.85M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: -19.15%
• EPS Growth: 10.90%
• Country: US
• Employees: 56
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.26
• Shares Outstanding: 97,986,630
• 10 Day Avg. Volume: 2,536,704
• 30 Day Avg. Volume: 1,853,623
• PEG Ratio: 0.49
• Price to Book (P/B): 3.84
• Price to Sales (P/S): 1143.94
• P/FCF Ratio: -3.89
• Enterprise Value/Market Cap: 1.06
• Enterprise Value/Revenue: 527.87
• Enterprise Value/Gross Profit: -2.94
• Enterprise Value/Ebitda: -1.31
• 1Y Price Target: $7.33
• Price Target Upside: 663.54% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $0.95 ▼(-0.94% Downside)

The score is held down primarily by very weak financial performance (large losses versus minimal revenue and significant cash burn) and the Nasdaq minimum-bid deficiency notice. Technicals provide only partial support (positive MACD and short-term strength) but are tempered by overbought signals and a weak longer-term trend. Valuation is also constrained by negative earnings and no indicated dividend support.

Positive Factors

Strong Equity Position

A strong equity position provides aTyr Pharma with a solid financial foundation, offering resilience against financial volatility and supporting long-term strategic investments.

Proprietary Platform

aTyr Pharma's proprietary platform offers a competitive edge in developing innovative therapies, potentially leading to breakthrough treatments and sustainable revenue streams.

Manageable Debt Levels

Low debt levels reduce financial risk and interest burden, allowing aTyr Pharma to focus resources on R&D and strategic growth initiatives.

Negative Factors

Declining Revenue

Declining revenue highlights challenges in product adoption or market penetration, potentially impacting long-term growth and financial sustainability.

Negative Cash Flow

Negative cash flow indicates operational inefficiencies and may limit aTyr Pharma's ability to fund new projects or withstand economic downturns, posing long-term financial risks.

Nasdaq Deficiency Notice

The Nasdaq deficiency notice poses a risk of delisting, which could limit access to capital markets and negatively impact investor confidence and stock liquidity.

aTyr Pharma Business Overview & Revenue Model

Company Description

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

How the Company Makes Money

aTyr Pharma generates revenue primarily through the development and commercialization of its therapeutic products. The company may receive funding from grants, collaborations, and partnerships with larger pharmaceutical entities that provide financial support in exchange for rights to develop and market certain products. Additionally, aTyr can earn revenue through milestone payments associated with the successful advancement of its drug candidates through clinical trials and regulatory approvals. Another potential revenue stream includes royalties from sales of partnered products, once they are commercialized.

aTyr Pharma Financial Statement Overview

Summary

Financials are dominated by very weak profitability and cash burn: TTM revenue is ~0.2M versus a large net loss (~75.1M) and deeply negative operating results. Cash flow is also materially negative (TTM operating cash flow ~-62.9M; FCF ~-63.0M). The main offset is a relatively stronger balance sheet with modest leverage (TTM debt-to-equity ~0.15) and sizable equity (~80.2M), but continued losses are eroding the capital base (very negative ROE).

Income Statement

Profitability remains very weak. In TTM (Trailing-Twelve-Months), the company generated only about $0.2M of revenue while reporting a large net loss (~$75.1M) and deeply negative operating results, indicating heavy R&D/operating spend relative to its current revenue base. Revenue has also trended down sharply from 2022 to 2024, and losses have generally widened versus prior years, which keeps the outlook on earnings quality and operating leverage pressured. A partial offset is that results are consistent with a clinical-stage biotech model, but the magnitude of losses versus revenue drives the low score.

Balance Sheet

The balance sheet is a relative strength. Leverage is modest with low debt versus equity (TTM debt-to-equity ~0.15), and equity remains sizable (~$80.2M TTM), providing some financial flexibility. However, ongoing large losses translate into very negative returns on equity (about -100% TTM) and equity has declined from earlier peaks, reflecting continued cash burn and accumulated deficits. Overall: conservative leverage, but weakening capital base if losses persist.

Cash Flow

Cash generation is weak with sustained cash burn. TTM (Trailing-Twelve-Months) operating cash flow is about -$62.9M and free cash flow is about -$63.0M, showing continued funding needs. There is a positive sign in that free cash flow improved versus the prior period (TTM free cash flow growth is positive), but cash flow remains meaningfully negative and closely tracks net losses, implying limited near-term self-funding capacity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	190.00K	235.00K	353.00K	10.39M	0.00	10.46M
Gross Profit	-34.17M	235.00K	353.00K	8.69M	-1.30M	-6.84M
EBITDA	-76.54M	-66.37M	-52.18M	-44.71M	-32.47M	-14.64M
Net Income	-75.12M	-64.02M	-50.39M	-45.34M	-33.77M	-16.22M
Balance Sheet
Total Assets	106.65M	96.83M	120.65M	95.79M	115.54M	38.73M
Cash, Cash Equivalents and Short-Term Investments	90.20M	72.13M	98.17M	66.15M	107.91M	31.69M
Total Debt	12.36M	13.28M	15.10M	11.53M	1.38M	2.24M
Total Liabilities	26.61M	27.00M	30.18M	24.50M	6.41M	7.24M
Stockholders Equity	80.23M	70.02M	90.66M	71.46M	109.30M	31.65M
Cash Flow
Free Cash Flow	-62.99M	-69.18M	-37.44M	-43.53M	-33.27M	-15.50M
Operating Cash Flow	-62.92M	-69.12M	-33.22M	-41.89M	-33.08M	-15.30M
Investing Cash Flow	-27.58M	17.23M	-20.13M	47.24M	-91.57M	6.90M
Financing Cash Flow	84.98M	39.86M	66.23M	5.45M	110.03M	16.14M

aTyr Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.96
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATYR, the sentiment is Positive. The current price of 0.96 is above the 20-day moving average (MA) of 0.75, above the 50-day MA of 0.75, and below the 200-day MA of 2.84, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 70.13 is Negative, neither overbought nor oversold. The STOCH value of 85.81 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATYR.

aTyr Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	57 Neutral	$114.24M	-1.56	-49.78%	―	-82.16%	14.58%
CNTX	57 Neutral	$217.75M	-8.82	-33.68%	―	―	69.30%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRLD	51 Neutral	$114.93M	-1.42	-103.99%	―	250.00%	15.15%
OKYO	51 Neutral	$78.61M	-16.75	―	―	―	―
ATYR	46 Neutral	$95.07M	-1.15	-103.22%	―	-19.15%	10.90%

aTyr Pharma Corporate Events

aTyr Pharma Receives Nasdaq Deficiency Notice

On December 4, 2025, aTyr Pharma, Inc. received a deficiency notice from Nasdaq, indicating that its stock price had fallen below the required $1.00 per share for 30 consecutive business days. This notice does not immediately affect the company’s listing, and aTyr Pharma has until June 2, 2026, to comply with the minimum bid price requirement. The company is exploring options to regain compliance, including a potential reverse stock split, to avoid delisting.

The most recent analyst rating on (ATYR) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on aTyr Pharma stock, see the ATYR Stock Forecast page.